|
A French trial investigating the results of interrupting Gleevec in metastatic GIST patients has been published (click for abstract). You can read a news story from the National Cancer Institute. Results indicate imatinib treatment should not be interrupted to avoid reactivation of metastases.
Back
|
We subscribe to the HONcode principles. 
